<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="16224"><DrugName>GP-683</DrugName><DrugSynonyms><Name><Value>GP-683</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>analgesic-sparing agent, Univ Texas</Value></Name><Name><Value>144928-17-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15891">Metabasis Therapeutics Inc</CompanyOriginator><CompaniesSecondary><Company id="15891">Metabasis Therapeutics Inc</Company><Company id="16290">SICOR Inc</Company><Company id="21864">University of Texas System</Company></CompaniesSecondary><CrossReferences><SourceEntity id="16224" type="Drug"><TargetEntity id="232190" type="siDrug">GP-1-683</TargetEntity></SourceEntity><SourceEntity id="15891" type="Company"><TargetEntity id="4295899182" type="organizationId">Metabasis Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="16290" type="Company"><TargetEntity id="5000595347" type="organizationId">Sicor Inc</TargetEntity></SourceEntity><SourceEntity id="21864" type="Company"><TargetEntity id="4296333708" type="organizationId">University of Texas System</TargetEntity></SourceEntity><SourceEntity id="119" type="ciIndication"><TargetEntity id="G40" type="ICD10"/><TargetEntity id="345" type="ICD9"/><TargetEntity id="10015037" type="MEDDRA"/><TargetEntity id="D004827" type="MeSH"/><TargetEntity id="-2005570698" type="omicsDisease"/><TargetEntity id="115" type="siCondition"/></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"/><TargetEntity id="D000758" type="MeSH"/><TargetEntity id="-564538434" type="omicsDisease"/><TargetEntity id="23" type="siCondition"/></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="1022" type="Action"><TargetEntity id="386" type="Mechanism">Adenosine Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00061" type="ciTarget"><TargetEntity id="2343845301323" type="siTarget">Adenosine kinase</TargetEntity><TargetEntity id="-1396341171" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="119">Epilepsy</Indication><Indication id="19">Anesthesia</Indication><Indication id="20">Pain</Indication></IndicationsSecondary><ActionsPrimary><Action id="1022">Adenosine kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action><Action id="70">Anticonvulsant agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N3</Code><Name>ANTI-EPILEPTICS</Name></Ephmra><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-12-20T14:58:09.000Z</LastModificationDate><ChangeDateLast>2007-04-04T16:18:19.000Z</ChangeDateLast><AddedDate>1997-10-16T13:05:31.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="16224" linkType="Drug"&gt;GP-683&lt;/ulink&gt; (an analog of &lt;ulink linkID="8203" linkType="Drug"&gt;GP-3269&lt;/ulink&gt;, qv) is an adenosine kinase inhibitor which was under investigation by Metabasis (formerly Gensia Sicor), as a potential agent which reduces the requirement for analgesia during the perioperative period, ie an analgesic-sparing agent [&lt;ulink linkID="266381" linkType="reference"&gt;266381&lt;/ulink&gt;]. However, by August 2000 this project had been discontinued [&lt;ulink linkID="377522" linkType="reference"&gt;377522&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; &lt;ulink linkID="16224" linkType="Drug"&gt;GP-683&lt;/ulink&gt; (1 mg/kg po) given to rats was able to block electric shock-induced seizure without any cardiovascular side effects [&lt;ulink linkID="335504" linkType="reference"&gt;335504&lt;/ulink&gt;] .&lt;/para&gt;&lt;para&gt;In anesthetized dogs, &lt;ulink linkID="16224" linkType="Drug"&gt;GP-683&lt;/ulink&gt; has been shown to increase levels of adenosine, and thereby reduce the concentration of &lt;ulink linkID="6027" linkType="Drug"&gt;desflurane&lt;/ulink&gt; required during surgery. Most importantly, the elevated levels of adenosine do not appear to elicit unwanted effects on the cardiovascular system [&lt;ulink linkID="286360" linkType="reference"&gt;286360&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15891">Metabasis Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="19">Anesthesia</Indication><StatusDate>2000-08-02T00:00:00.000Z</StatusDate><Source id="377522" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21864">University of Texas System</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="19">Anesthesia</Indication><StatusDate>2000-08-02T00:00:00.000Z</StatusDate><Source id="377522" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15891">Metabasis Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="119">Epilepsy</Indication><StatusDate>2000-08-02T00:00:00.000Z</StatusDate><Source id="377522" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15891">Metabasis Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate>2000-08-02T00:00:00.000Z</StatusDate><Source id="377522" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="21864">University of Texas System</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="19">Anesthesia</Indication><Source id="266374" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16290">SICOR Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>1997-10-16T00:00:00.000Z</StatusDate><Source id="266381" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16290">SICOR Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>1997-11-01T00:00:00.000Z</StatusDate><Source id="266381" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16290">SICOR Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate>1999-08-06T00:00:00.000Z</StatusDate><Source id="335504" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00061"><Name>Adenosine kinase</Name><SwissprotNumbers><Swissprot>O49923</Swissprot><Swissprot>O93919</Swissprot><Swissprot>P47143</Swissprot><Swissprot>P55262</Swissprot><Swissprot>P55263</Swissprot><Swissprot>P55264</Swissprot><Swissprot>P78825</Swissprot><Swissprot>P83734</Swissprot><Swissprot>P83736</Swissprot><Swissprot>Q64640</Swissprot><Swissprot>Q9TVW2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>C[C@@H]1[C@H]([C@H]([C@@H](O1)n2cc(c3c2ncnc3Nc4ccccc4)c5ccccc5)O)O</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2201171" number="WO-09640705" title="C-4` modified adenosine kinase inhibitors."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>